Methylene Blue — Redox / Mitochondrial Agent

Evidence-supportedB/CgradePlausibility · Plausible for known uses; longevity speculativePharmacologic / Redox Agents

Evidence-supported · Evidence-supported

Methemoglobinemia (FDA-approved).

Off-label · Insufficient-evidence

Longevity / nootropic / anti-aging / 'mitochondrial' supplement use.

Pharmacologic, not energy medicine: FDA-approved for methemoglobinemia; popular off-label as a longevity / nootropic supplement (speculative). Family = Pharmacologic / redox agents — dominant axis is redox / mitochondrial electron transport. Its photodynamic (PDT) facet cross-refs the Photonic family, but methylene blue is NOT photobiomodulation.

Origin & lineage

Old drug; redox / mitochondrial / photodynamic.

Claimed mechanism

Electron cycling and mitochondrial electron-transport support; a separate photodynamic-therapy (PDT) facet.

Plausibility

Plausible for known uses; longevity speculative.

Evidence — grade B/C

FDA-approved for methemoglobinemia (B); off-label longevity / nootropic use speculative (C).

Cross-reference

Photonic (photodynamic-therapy facet) — cross-reference only; methylene blue is NOT photobiomodulation.

Market

Makers: Pharma generics + supplement vendors.
Models: USP methylene blue; supplement formulations.
Price: ~$10–100.

Kernel — keep vs set aside

Keep — real substrate

Real pharmacology (redox / mitochondrial electron transport; approved methemoglobinemia use).

Set aside — claim

'Frequency' / anti-aging branding is misleading; off-label longevity / nootropic use is speculative, not established.

Regulatory status by jurisdiction

Registration or clearance is a market-access fact, never proof of efficacy.

US — FDA	Prescription for approved uses (methemoglobinemia); supplement-channel use varies.
EU — MDR	Prescription for approved uses.
Russia	Not specified in source.
China — NMPA	Not specified in source.
Australia — TGA	Not specified in source.

Sources

No verified primary source available — claims carried as unverified; not fabricated.